Comments
Loading...

Cabaletta Bio Analyst Ratings

CABANASDAQ
Logo brought to you by Benzinga Data
$1.96
0.021.07%
After Hours: 8:45 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$50.00
Lowest Price Target1
$3.00
Consensus Price Target1
$22.38

Cabaletta Bio Analyst Ratings and Price Targets | NASDAQ:CABA | Benzinga

Cabaletta Bio Inc has a consensus price target of $22.38 based on the ratings of 13 analysts. The high is $50 issued by Cantor Fitzgerald on June 21, 2024. The low is $3 issued by Wells Fargo on April 1, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citigroup, and Guggenheim on June 11, 2025, May 16, 2025, and May 16, 2025, respectively. With an average price target of $21 between HC Wainwright & Co., Citigroup, and Guggenheim, there's an implied 1025.76% upside for Cabaletta Bio Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
4
1
Apr
3
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Citigroup
Guggenheim
Wells Fargo
UBS

1calculated from analyst ratings

Analyst Ratings for Cabaletta Bio

Buy NowGet Alert
06/11/2025Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
05/16/2025Buy Now596.9%Citigroup
Samantha Semenkow33%
$17 → $13MaintainsBuyGet Alert
05/16/2025Buy Now1240.2%Guggenheim
Yatin Suneja56%
$23 → $25MaintainsBuyGet Alert
05/15/2025Buy Now1240.2%Guggenheim
Yatin Suneja56%
$23 → $25MaintainsBuyGet Alert
04/01/2025Buy Now60.82%Wells Fargo
Derek Archila62%
$6 → $3MaintainsEqual-WeightGet Alert
04/01/2025Buy Now1132.98%Guggenheim
Yatin Suneja56%
$23 → $23ReiteratesBuy → BuyGet Alert
04/01/2025Buy Now275.25%UBS
Trung Huynh71%
$10 → $7MaintainsBuyGet Alert
04/01/2025Buy Now1079.37%Morgan Stanley
Michael Ulz66%
$30 → $22MaintainsOverweightGet Alert
04/01/2025Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
02/18/2025Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
01/17/2025Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
12/20/2024Buy Now221.65%Evercore ISI Group
Gavin Clark-Gartner39%
$15 → $6DowngradeOutperform → In-LineGet Alert
12/19/2024Buy Now221.65%Wells Fargo
Derek Archila62%
$12 → $6DowngradeOverweight → Equal-WeightGet Alert
11/18/2024Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
11/15/2024Buy Now543.29%Wells Fargo
Derek Archila62%
$20 → $12MaintainsOverweightGet Alert
11/15/2024Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
10/10/2024Buy Now436.08%UBS
Trung Huynh71%
→ $10Initiates → BuyGet Alert
09/17/2024Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$25 → $25ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now972.16%Wells Fargo
Derek Archila62%
$35 → $20MaintainsOverweightGet Alert
08/12/2024Buy Now704.12%Evercore ISI Group
Gavin Clark-Gartner39%
$25 → $15MaintainsOutperformGet Alert
08/09/2024Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$30 → $25MaintainsBuyGet Alert
06/21/2024Buy Now2580.39%Cantor Fitzgerald
Josh Schimmer55%
$50 → $50ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy Now1615.45%Stifel
Ben Burnett9%
$32 → $32MaintainsBuyGet Alert
06/14/2024Buy Now1508.23%HC Wainwright & Co.
Douglas Tsao53%
$30 → $30ReiteratesBuy → BuyGet Alert
05/24/2024Buy Now1508.23%HC Wainwright & Co.
Douglas Tsao53%
$30 → $30ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now1508.23%HC Wainwright & Co.
Douglas Tsao53%
$30 → $30ReiteratesBuy → BuyGet Alert
04/05/2024Buy Now2580.39%Cantor Fitzgerald
Joshua Schimmer45%
$50 → $50ReiteratesOverweight → OverweightGet Alert
04/04/2024Buy Now1508.23%Citigroup
Samantha Semenkow33%
$26 → $30MaintainsBuyGet Alert
03/22/2024Buy Now2580.39%Cantor Fitzgerald
Joshua Schimmer45%
$50 → $50ReiteratesOverweight → OverweightGet Alert
03/22/2024Buy Now1776.27%Wells Fargo
Derek Archila62%
$34 → $35MaintainsOverweightGet Alert
03/22/2024Buy Now1508.23%HC Wainwright & Co.
Douglas Tsao53%
$25 → $30MaintainsBuyGet Alert
03/21/2024Buy Now1615.45%Stifel
Ben Burnett9%
$31 → $32MaintainsBuyGet Alert
02/05/2024Buy Now1829.88%Jefferies
Kelly Shi43%
→ $36Initiates → BuyGet Alert
11/29/2023Buy Now1240.2%Morgan Stanley
Michael Ulz66%
$28 → $25MaintainsOverweightGet Alert
11/29/2023Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
→ $25ReiteratesBuy → BuyGet Alert
11/15/2023Buy Now2580.39%Cantor Fitzgerald
Joshua Schimmer45%
$40 → $50MaintainsOverweightGet Alert
11/10/2023Buy Now1722.67%Wells Fargo
Derek Archila62%
$39 → $34MaintainsOverweightGet Alert
11/10/2023Buy Now1240.2%HC Wainwright & Co.
Douglas Tsao53%
$17 → $25MaintainsBuyGet Alert
11/08/2023Buy Now1401.02%Morgan Stanley
Michael Ulz66%
$16 → $28MaintainsOverweightGet Alert
10/24/2023Buy Now2044.31%Cantor Fitzgerald
Joshua Schimmer45%
→ $40Initiates → OverweightGet Alert
10/19/2023Buy Now1561.84%Stifel
Ben Burnett9%
→ $31Initiates → BuyGet Alert
10/04/2023Buy Now811.33%HC Wainwright & Co.
Douglas Tsao53%
→ $17ReiteratesBuy → BuyGet Alert
09/18/2023Buy Now1990.7%Wells Fargo
Derek Archila62%
$14 → $39MaintainsOverweightGet Alert
09/05/2023Buy Now1079.37%Citigroup
Samantha Semenkow33%
→ $22Initiates → BuyGet Alert
08/14/2023Buy Now1722.67%Guggenheim
Yatin Suneja56%
→ $34ReiteratesBuy → BuyGet Alert
08/11/2023Buy Now811.33%HC Wainwright & Co.
Douglas Tsao53%
$15 → $17MaintainsBuyGet Alert
07/18/2023Buy Now1722.67%Guggenheim
Yatin Suneja56%
→ $34Initiates → BuyGet Alert
05/17/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
→ $15ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
→ $15ReiteratesBuy → BuyGet Alert
05/03/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
→ $15Reiterates → BuyGet Alert
04/10/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
→ $15Reiterates → BuyGet Alert
04/03/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
→ $15Reiterates → BuyGet Alert
03/22/2023Buy Now543.29%Chardan Capital
Geulah Livshits47%
→ $12Reiterates → BuyGet Alert
03/17/2023Buy Now436.08%Mizuho
Uy Ear61%
→ $10Reiterates → BuyGet Alert
03/17/2023Buy Now704.12%HC Wainwright & Co.
Douglas Tsao53%
$11 → $15MaintainsBuyGet Alert
02/17/2023Buy Now489.69%HC Wainwright & Co.
Douglas Tsao53%
→ $11Reiterates → BuyGet Alert
01/27/2023Buy Now757.72%Morgan Stanley
Michael Ulz66%
→ $16UpgradeEqual-Weight → OverweightGet Alert
01/03/2023Buy Now650.51%Wells Fargo
Derek Archila62%
$4 → $14MaintainsOverweightGet Alert
11/11/2022Buy Now543.29%Chardan Capital
Geulah Livshits47%
$13 → $12MaintainsBuyGet Alert
09/14/2022Buy Now114.43%Wells Fargo
Derek Archila62%
$14 → $4MaintainsOverweightGet Alert
08/30/2022Buy Now60.82%Morgan Stanley
Michael Ulz66%
$15 → $3DowngradeOverweight → Equal-WeightGet Alert
08/12/2022Buy Now596.9%Chardan Capital
Geulah Livshits47%
$17 → $13MaintainsBuyGet Alert

FAQ

Q

What is the target price for Cabaletta Bio (CABA) stock?

A

The latest price target for Cabaletta Bio (NASDAQ:CABA) was reported by HC Wainwright & Co. on June 11, 2025. The analyst firm set a price target for $25.00 expecting CABA to rise to within 12 months (a possible 1240.20% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cabaletta Bio (CABA)?

A

The latest analyst rating for Cabaletta Bio (NASDAQ:CABA) was provided by HC Wainwright & Co., and Cabaletta Bio reiterated their buy rating.

Q

When was the last upgrade for Cabaletta Bio (CABA)?

A

The last upgrade for Cabaletta Bio Inc happened on January 27, 2023 when Morgan Stanley raised their price target to $16. Morgan Stanley previously had an equal-weight for Cabaletta Bio Inc.

Q

When was the last downgrade for Cabaletta Bio (CABA)?

A

The last downgrade for Cabaletta Bio Inc happened on December 20, 2024 when Evercore ISI Group changed their price target from $15 to $6 for Cabaletta Bio Inc.

Q

When is the next analyst rating going to be posted or updated for Cabaletta Bio (CABA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cabaletta Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cabaletta Bio was filed on June 11, 2025 so you should expect the next rating to be made available sometime around June 11, 2026.

Q

Is the Analyst Rating Cabaletta Bio (CABA) correct?

A

While ratings are subjective and will change, the latest Cabaletta Bio (CABA) rating was a reiterated with a price target of $25.00 to $25.00. The current price Cabaletta Bio (CABA) is trading at is $1.87, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch